SATT Ile-de-France Innov (idfinnov) is a regional TTO (Technology Transfer Organisation) with exclusive rights to detect, seed-fund and commercialize technology stemming from academic research centers across the Paris Metropolitan Area.
This territory has more than 17,000 researchers, clinicians and PhDs, and hosts the strongest cluster for clinical expertise in France. idfinnov operates as a maturation fund and will invest over €6m/year to finance proof of concepts and prototyping projects on carefully selected innovations.
SATT Nord (technology transfer office) was created in July 2012 and designed to cover three administrative regions (the Nord-Pas de Calais, Champagne-Ardenne and Picardie regions); it is located at the heart of a European crossroad and is a tool for the creation and development of companies through innovation.
With its multidisciplinary and professional team, SATT Nord identifies projects and supports their further development and intellectual protection through to their commercialization through transfers or the founding of companies targeted at the local, national or international industrial network. SATT Nord works in close collaboration with academic research laboratories
Founded in 1888 and still privately owned today, the Institut Pasteur (IP) has produced nine winners of the Nobel Prize for Medicine in its laboratories. Its international renown is built around a network of 40 Institutes worldwide, including three major satellite Institutes in South Korea, Hong Kong and China.
The Institut Pasteur manages an annual budget of €200 million and a team of 2,500 researchers from 2011. It has exceptional expertise in both upstream research and clinical development. For instance, the IP has built up the world’s largest epidemiological network for anti-infective treatments.
It has a very strong track record and organisation for technology transfer, and has long been considered as the benchmark model both in France and abroad, notably with: renowned partners in the pharmaceutical industry and 11 companies created since 1998 (including three listed on the stock market).
The SATT Conectus Alsace® was the first SATT (Société d’Accélération de Transfert de technologie) to be created in France in 2012. Financed by the French State, its activities spread from management of intellectual properties, technology maturation, licensing out and service offering in the field of collaborative research and technology transfer.
Kurma Partners aims to bring the best European research institutes together within a network of international alliances in order to be able to detect high-potential projects.
Cancer Research Technology (CRT) is a specialist commercialisation and development company. Owned by Cancer Research UK, CRT has exclusive rights to intellectual property from Cancer Research UK funded research – more than £300M annually. CRT has 3 marketed drugs and over 30 partnered agents in preclinical and clinical development. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines or diagnostics. Working closely with leading international cancer scientists, CRT establishes links with commercial partners.
Founded in 1996 on the initiative of the Flemish government, VIB groups the best Flemish research universities – Ghent University, K.U Leuven, the University of Antwerp and Vrije Universiteit Brussel – together in one virtual research institute. The institute employs 1,200 researchers. The leading international organisation for molecular and cellular biology, VIB’s fundamental and applied research work covers medical research and plant biology. VIB is recognised as one of the European leaders for technology transfer in life sciences.
Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that a total of 21 substances have first-in-class potential.
Commercialization of the quality research taking place in Leiden is a key priority of both Leiden University and Leiden University Medical Center (LUMC). Not only is the research activity itself strengthened, but also the output can be effectively utilized by society for economic and clinical benefit. The role of LURIS is to facilitate this process for the University and LUMC.
Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator’s model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. Cydan was launched in 2013 by a management team with extensive drug development and commercialization experience and with financing from leading investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities. The accelerator is based in Cambridge, Mass.